|
| |
CytogenCytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide), and SOLTAMOX™ (tamoxifen citrate) to the U.S. oncology market. QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer, and SOLTAMOX is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. In early 2007, Cytogen introduced its fourth approved oncology product to the U.S. market, CAPHOSOL®, an advanced electrolyte solution for the treatment of oral mucositis and dry mouth that is approved in the U.S. as a prescription medical device. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy focuses on attaining sustainable growth through clinical, commercial, and strategic initiatives.
| Contact Details: |
| 650 College Road East |
| Princeton |
| NJ |
| 08540 |
| United States of America |
| Tel: | (800) 833-3533 or (609) 750-8200 |
| Fax: | (609) 452-2476 |
| Email: | |
| WWW: | www.cytogen.com/
|
|
Loading...
|
Recent Publications by Cytogen: |  |
Cytogenetic study of professional rescue rangers of Russian Ministry of Emergencies.
Cytogenetic studies in rescue rangers of the Russian Ministry of... | 3rd October, 2008
| A. M. Nikiforov National Center of Urgent and Radiation Medicine, Ministry
| Bull Exp Biol Med. 2007 Oct;144(4):555-8.
|
Tumoral calcinosis due to GALNT3 C.516-2A >T mutation in a black African family.
Familial Tumoral Calcinosis (FTC) is a rare autosomal recessive disorder... | 10th September, 2008
| Unite de Biologie Humaine, Faculte des Sciences de la Sante, Cotonou,
| Genet Couns. 2008;19(2):183-92.
|
Indium-111 capromab pendetide in the management of recurrent prostate cancer.
The provision of accurate prognostic information is a long-standing goal... | 28th March, 2008
| The George Washington University, Washington, DC, 650 College Road East,
| Expert Rev Anticancer Ther. 2008 Feb;8(2):175-81.
DOI Direct Link |
The emergence of imaging technology in advanced prostate cancer.
Rapid advances in imaging technology have whetted our collective appetites... | 7th March, 2008
| Department of Medical Affairs, Cytogen Corporation, Princeton, NJ, USA.
| Can J Urol. 2007 Dec;14 Suppl 1:32-8.
|
Wolf Hirshhorn syndrome in a case of ring chromosome 4: phenotype and molecular cytogenetic findings.
Ring chromosome 4 associates concomitant loss of the telomeric 4p and 4q... | 17th October, 2006
| Unite de Biologie Humaine, Faculte des Sciences de la Sante, Cotonou,
| Genet Couns. 2006;17(1):35-40.
|
→View more Cytogen research publications. |
Press Releases on Cytogen:
|
 |
| Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and Predicting Disease Free Survival |
4th November, 2009 |
EUSA Pharma (USA), Inc. |
LANGHORNE, Pa., Nov. 4 /PRNewswire/ -- EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a
|
| New Report Just Published: World Prostate Cancer Therapeutics Market Report |
7th July, 2009 |
Reportlinker |
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.
World Prostate Cancer Therapeutics Market
http://www.reportlinker.com/p0119471/World
|
| DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller |
7th July, 2009 |
DOR BioPharma, Inc. |
PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it recently
|
| Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer |
26th May, 2009 |
Strategic Diagnostics Inc. |
NEWARK, Del., May 26 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) - today announced that Kevin J. Bratton has joined the Company as its Vice President of Finance and Chief
|
| EUSA Pharma Completes the European Launch of CAPHOSOL(R) for Prevention and Treatment of Oral Mucositis Caused by Cancer Therapy |
31st March, 2009 |
EUSA Pharma Inc |
DOYLESTOWN, Pennsylvania and OXFORD, England, March 31 /PRNewswire/ --
EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company
focused on oncology, pain control and
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 514 times since April 2007, the link to the organisation's website has been followed 83 times Recent Search Terms used to find this page: cytogen | CAPHOSOL U.S. patent | . Search for more companies in Princeton Search for more companies in NJ This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Cytogen |
